IQVIA, a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.
IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulatory strategy for DCT implementation and on business process transformation for implementing a DCT model, as well as a focus on implementing healthcare-grade AI across the value chain, with novel GenAI tools to transform patient experience.”
“Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay,” wrote Dr. Nimita Limaye, IDC’s research VP, Life Sciences R&D Strategy and Technology. “The focus is on integration, integration of technologies, integration of touch points to create unified and meaningful experiences, and the alignment of technologies and operating models. The way the industry is perceiving DCTs is maturing. No, DCTs aren’t going away. Instead, DCTs are becoming a ‘business as usual’ strategy today.”
Also Read: Qaelon & RevMedica Partner to Advance Surgical Stapling
Decentralized clinical trials, which gained popularity during the COVID-19 pandemic, are clinical trial studies that use telemedicine and mobile technologies to perform trial activities outside of a traditional clinical site. For example, patients can be monitored remotely using wearable devices, and the use of digital tools to communicate and collect data means patients are required to make fewer visits to trial sites.
IQVIA’s integrated strategy helps customers adopt, run and execute decentralized trial approaches, delivering a unique and differentiating experience.
“At IQVIA, we are proud to be a leader in decentralized clinical trials and remain focused on delivering cutting-edge technology solutions that enhance patient and site experiences and drive healthcare forward,” said Susan Hill, senior vice president, product management, Digital Products & Solutions at IQVIA.
“Being named a Leader in the IDC MarketScape report highlights our commitment to revolutionizing clinical trials through innovation and excellence. We are honored to receive this distinction and empower our customers to achieve outstanding results,” said Alison Liddy, senior vice president for Patient and Site Centric Solutions at IQVIA.
Source: Businesswire